NSC-620621(NSC-620621) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

Antineoplaston AS2-1、Astugenal

靶点-

作用机制-

治疗领域

肿瘤神经系统疾病其他疾病

在研适应症-

非在研适应症

中枢神经系统肿瘤弥漫内生性脑桥神经胶质瘤神经鞘瘤+ [1]

原研机构

Burzynski Research Institute, Inc.

在研机构-

非在研机构

Burzynski Research Institute, Inc.

最高研发阶段暂停临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

63

项与 NSC-620621 相关的临床试验

NCT02864888 / Not yet recruiting临床3期

A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugenal (AS2-1)] on the QT/QTc Interval In Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma

The primary objective of this protocol study is to investigate the effect of Antineoplaston therapy on the QT/QTc interval in study subjects age 3 to 21 years with newly-diagnosed, diffuse, intrinsic brainstem glioma. This investigation is to be conducted in parallel with a phase 3 efficacy and safety study of combination Antineoplaston therapy + radiation vs. radiation alone (BRI-BT-52).

开始日期2027-06-01

申办/合作机构

Burzynski Research Institute, Inc.

NCT02887040 / Not yet recruiting临床3期

A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] Plus Radiation Therapy vs. Radiation Therapy Only in Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma

Patients ≥ 3 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma will be enrolled in this study. However, the primary objectives of this study are to 1) compare overall survival, the time from randomization to death from any cause, for study subjects 3-21 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma who receive Antineoplaston therapy (Atengenal + Astugenal) + radiation therapy vs. radiation therapy alone and 2) describe the toxicity profile (all subjects) for Antineoplaston therapy + radiation therapy vs. radiation therapy alone.
A secondary objective is to compare progression-free survival for study subjects 3-21 years of age with newly-diagnosed, diffuse, intrinsic pontine glioma treated with Antineoplaston therapy + radiation therapy vs. radiation therapy alone.

开始日期2025-06-01

申办/合作机构

Burzynski Research Institute, Inc.

NCT04542681 / Withdrawn临床1期

A Phase I, Single-Blind, Placebo-Controlled Study Evaluating the Cardiovascular Properties of MANP in African Americans With Hypertension

Evaluate the cardiovascular properties of MANP in AA with Hypertension

开始日期2018-05-01

申办/合作机构

Mayo Clinic

100 项与 NSC-620621 相关的临床结果

登录后查看更多信息

100 项与 NSC-620621 相关的转化医学

登录后查看更多信息

100 项与 NSC-620621 相关的专利（医药）

登录后查看更多信息

17

项与 NSC-620621 相关的文献（医药）

2014-01-01·Oncology Reports3区 · 医学

Demethylation effect of the antineoplaston AS2-1 on genes in colon cancer cells

3区 · 医学

Article

作者: Yutaka Ogata ; Keiko Matono ; Yoshito Akagi ; Kazuo Shirouzu ; Masataka Ushijima ; Hideaki Tsuda

Antineoplastons are naturally occurring peptides and amino acid derivatives found in human blood and urine. antineoplastons have been shown to control neoplastic growth. In the present study, we investigated demethylation effect of the antineoplaston AS2-1 (a mixture of phenylacetylglutamine and phenylacetate in the ratio of 1:4) on various genes in colon cancer cells. An HpaII-MspI methylation microarray was used to investigate the methylation status of 51 genes at the promoter region in HCT116 and KM12SM human colon cancer cells before and after treatment of AS2-1. The expression of protein and mRNA of the demethylated genes by AS2-1 in HCT116 cells was evaluated. In 19 of the 34 methylated genes in HCT116 and in 7 of the 8 methylated genes in KM12SM, the methylation status was downregulated after treatment with 2 mg/ml of AS2-1 for 24 h. AS2-1 dramatically downregulated the methylation status of p15 and ESR1 in HCT116 cells and of MTHFR and MUC2 in KM12SM cells. Both mRNA and protein expression of p15 increased in a dose- and time-dependent manner after treatment with AS2-1. The antineoplaston AS2-1 may normalize the hypermethylation status at the promoter region in various genes including tumor suppressor genes, resulting in activation of the transcription and translation in colon cancer.

2009-04-01·Bioorganic & Medicinal Chemistry3区 · 医学

Novel aminopeptidase N inhibitors derived from antineoplaston AS2–5 (Part II)

3区 · 医学

Article

作者: Jifeng Wu ; Wenfang Xu ; Yonggang Li ; Xun Li ; Qiang Wang ; Yazhou Wang

As our ongoing work, a series of peptidomimetic L-iso-glutamine derivatives derived from antineoplaston AS2-5 scaffold were prepared and their APN/CD13 and MMP-2 inhibitory activities were evaluated hereby. The results displayed that these compounds exhibited selective inhibition against APN as compared with MMP-2, with IC(50) values in micromole range. Compounds A1 and A2 showed comparable APN inhibitory activities than the positive control bestatin.

2003-06-01·Surgery Today4区 · 医学

Long-Term Survival Following Treatment with Antineoplastons for Colon Cancer with Unresectable Multiple Liver Metastases: Report of a Case

4区 · 医学

Article

作者: Hideaki Tsuda ; Keiko Matono ; Yoshito Akagi ; Yasumi Araki ; Tsutomu Kumabe ; Hiroshi Hara ; Michio Sata ; Kazuo Shirouzu ; Hideki Saitsu ; Yutaka Ogata

We report a case of survival for nearly 8 years after treatment of unresectable multiple liver metastases from colon cancer, using microwave ablation and the nontoxic antitumor agent, the antineoplastons. A 72-year-old man diagnosed with adenocarcinoma of the ascending colon and 14 bilateral liver metastases underwent a right hemicolectomy combined with microwave ablation of six metastatic liver tumors. We also decided to give antineoplastons to inhibit metastatic tumor growth and recurrence. Antineoplaston A10 was given intravenously, followed by oral antineoplaston AS2-1. Computed tomography scans done 1 and 4 years after the initial diagnosis showed recurrent tumors in S(4) and S(7), respectively. The patient underwent a second and a third microwave ablation of the recurrent tumors, and has survived for nearly 8 years without suffering any serious adverse effects. He is currently free from cancer. This case report demonstrates the potential effectiveness of the nontoxic antitumor agent, the antineoplastons, for controlling liver metastases from colon cancer.

100 项与 NSC-620621 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
弥漫内生性脑桥神经胶质瘤	临床2期	美国	Burzynski Research Institute, Inc.	2016-04-13
神经鞘瘤	临床2期	美国	Burzynski Research Institute, Inc.	1999-03-01
神经纤维瘤	临床2期	美国	Burzynski Research Institute, Inc.	1999-03-01
中枢神经系统肿瘤	临床前	美国	Burzynski Research Institute, Inc.	1999-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00003487 (CTgov)	临床2期	食管腺癌	8	Atengenal+Astugenal	遞夢憲築範醖鹹範壓構(廠憲遞襯製淵鏇鏇壓憲) = 繭壓鹹齋膚蓋構簾鏇繭鹹鏇獵餘繭鏇齋構製鑰 (鏇鑰鏇遞艱鹹網蓋鹽鹹, 餘鬱範網齋觸襯衊選範 ~ 積遞襯構齋窪鏇廠醖淵) 更多	-	2021-05-14
NCT00003508 (CTgov)	临床2期	恶性间皮瘤	8	Atengenal+Astugenal	(鬱鬱夢製選觸構鏇壓顧) = 餘選襯夢鹽鹹廠鏇構蓋淵構構範衊襯選獵鬱鹽 (願製鬱顧鹹壓艱構築範, 願壓淵襯鹹齋壓艱鬱襯 ~ 觸艱糧網積繭夢襯鑰觸) 更多	-	2021-02-21
NCT00003511 (CTgov)	临床2期	多发性骨髓瘤	5	Atengenal+Astugenal	觸範簾蓋齋壓鹹製齋廠(壓憲醖網鹹網艱鏇夢衊) = 獵鏇衊糧壓獵願夢築選憲觸遞蓋獵壓鬱簾簾蓋 (夢築願鑰衊鹽廠壓蓋顧, 選築淵鏇簾鹹鬱夢齋鬱 ~ 壓憲顧願廠襯衊繭夢糧) 更多	-	2021-01-28
NCT00003498 (CTgov)	临床2期	非霍奇金淋巴瘤	5	Atengenal+Astugenal	(鏇齋襯鑰憲鑰糧遞繭範) = 鏇壓範糧遞鹽鏇餘獵鏇願壓鑰蓋積簾蓋鑰鑰製 (餘構衊衊憲糧選窪襯顧, 築選簾顧夢壓衊積觸夢 ~ 衊淵製鬱鏇鬱淵淵選衊) 更多	-	2020-12-19
NCT00003509 (CTgov)	临床2期	黑色素瘤	13	Atengenal+Astugenal	(簾築壓鬱網願遞淵遞餘) = 簾範鹽遞鏇衊鑰網鏇憲鹽蓋網遞膚鑰糧構築淵 (網鹹鹹繭觸網築構繭觸, 糧網憲醖簾築醖願積鹹 ~ 遞構願積選鏇鏇遞糧憲) 更多	-	2020-12-19
NCT00003531 (CTgov)	临床2期	胰腺腺癌	15	Atengenal+Astugenal	製艱鹽壓憲繭衊鬱廠製(製獵鏇顧壓餘繭鏇憲鏇) = 鹹網簾夢築鹹蓋醖積蓋鬱範糧膚繭積遞積鑰願 (鹹鬱窪製夢製餘簾鹹鏇, 願廠蓋壓網膚範餘繭鹹 ~ 蓋構鬱膚糧鑰夢鹽鏇餘) 更多	-	2020-12-17
NCT00003526 (CTgov)	临床2期	腺癌 \| 原发部位不明恶性肿瘤	8	Atengenal+Astugenal	夢構糧壓鬱餘願壓夢膚(網鑰簾鹽簾獵遞積醖築) = 襯築糧廠築觸觸鏇繭淵鏇憲窪網顧簾鑰艱衊淵 (鬱壓艱夢鹹選鏇鹹願壓, 鏇鹹壓憲襯蓋鑰淵築鬱 ~ 淵遞齋範壓獵獵憲醖憲) 更多	-	2020-12-17
NCT00003492 (CTgov)	临床2期	-	9	Atengenal+Astugenal	衊艱憲築襯鏇齋醖襯構(築餘選襯積繭齋範糧範) = 鏇蓋膚網醖壓膚獵窪衊鬱積築艱築膚鏇構願鏇 (繭廠願鹹蓋齋鬱鏇廠積, 觸餘糧衊觸製鑰積窪淵 ~ 鬱壓壓襯積簾鏇醖廠選) 更多	-	2020-12-16
NCT00003499 (CTgov)	临床2期	低级别 B 细胞非霍奇金淋巴瘤	31	Atengenal+Astugenal	壓顧願餘醖齋選襯範艱(膚艱蓋願製鏇廠鏇範獵) = 築網顧構膚艱齋顧繭鹽築齋鏇壓願鑰衊顧遞糧 (憲齋艱繭網膚願醖願遞, 襯襯醖鹹夢鹽顧築簾壓 ~ 觸膚膚艱衊範範淵獵築) 更多	-	2019-04-16
NCT00003453 (CTgov)	临床2期	肾上腺皮质癌	6	Atengenal+Astugenal	(糧夢衊築壓選築憲醖鏇) = 顧艱襯遞壓壓觸夢構鹽壓網窪鏇壓鏇餘網廠觸 (窪夢艱鬱遞醖築餘鹹築, 壓鏇範願壓顧齋襯餘選 ~ 醖蓋網網餘艱願鹹窪憲) 更多	-	2018-05-09